Document is current
Any future updates will be listed below
-
Authors
Papaccio, Federica
García-Mico, Blanca
Gimeno-Valiente, Francisco
Cabeza-Segura, Manuel
Gambardella, Valentina
Gutiérrez-Bravo, María Fernanda
Alfaro-Cervelló, Clara
Martinez-Ciarpaglini, Carolina
Rentero-Garrido, Pilar
Zúñiga-Trejos, Sheila
Carbonell-Asins, Juan Antonio
Fleitas, Tania
Roselló, Susana
Huerta, Marisol
Sánchez del Pino, Manuel M.
Sabater, Luís
Roda, Desamparados
Tarazona, Noelia
Cervantes, Andrés http://orcid.org/0000-0003-3806-3691
Castillo, Josefa
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/01508, PI21/0693, PI18/01909, PI18/01909, PI21/00689, PI21/00689, Joan Rodés contract JR17/00026, Joan Rodés contract JR21/00042, Joan Rodés contract JR20/00005, Joan Rodés contract JR16/00040, 2018 grant)
Fundación Científica Asociación Española Contra el Cáncer (predoctoral grant)
Generalitat Valenciana (APOSTD/2021/168, PROMETEU/2019/065)
Universitat de València and INCLIVA (VLC Bioclinic grant 2021/257, VLC Bioclinic grant 2021/257)
European Society for Medical Oncology (ESMO Translational Research Fellowship 2018-2020)
Conselleria d'Educació, Investigació, Cultura i Esport (GRISOLIAP/2017/161)
Ministerio de Ciencia e Innovación (PID2020-119111GB-I00)
- License Information
-
More Information
Article History
Received: 28 September 2022
Accepted: 28 December 2022
First Online: 6 January 2023
Declarations
:
: The study was approved by the ethic committee of Hospital Clínico Universitario de Valencia (2018/063, 2021/083), and all patients signed an informed consent.
: Not applicable.
: AC declares institutional research funding from Genentech, Merck Serono, BMS, MSD, Roche, Beigene, Bayer, Servier, Eli-Lilly, Novartis, Takeda, Astellas, Natera and Fibrogen and advisory board or speaker fees from Amgen, Merck Serono, Roche, Bayer, Servier and Pierre Fabre in the last five years. DR declares institutional research funding from Tesaro, AbbVie, Novartis, Merus, Roche, Relay Therapeutics, HiFiBiO inc. VG declares institutional research funding from Cellcentric, Roche, Black Diamond Therapeutics, Seagen, Kinnate Biopharma, Genentech, Bayer, Eli-Lilly, Boehringher. TF declares institutional research funding from Zymeworks, AstraZeneca, Amgen, Beigene, Adaptimmune, Daiichi Sankyo. SR declares institutional research funding from Novartis, Nouscom, Pfizer, Scandion Oncology, Ability Pharmaceuticals, Pierre Fabre, Mirati Therapeutics. FP declares institutional research funding from Merck Serono. All remaining authors have declared no conflict of interest.
